This large multicentre study of peritonitis offers insights into the aetiology and outcomes of infectious complications of chronic PD in India that are germane to clinical decision-making.
Introduction: Acute Kidney Injury is commonly present in Covid-19 hospitalised patients whereas chronic kidney
disease and end-stage renal disease are also common comorbidities in patients who develop severe COVID-19. These
patients require antiviral medication as early as possible but there is no current guidelines for use of Remdesivir therapy in these patents and drug
is not used initially in these patients. Antiviral strategies are desperately needed in this population to treat these patients as early as possible.
Material And Methods: We conducted an observational, retrospective cohort study of adults with COVID-19 conrmed by RT-PCR who had
eGFR < 30mL/min/1.73m2 or received RRT prior to receiving at least one dose of Remdesivir. eGFR was estimated from the serum creatinine
value just prior to the rst dose of Remdesivir using the Chronic Kidney Disease Epidemiology Collaboration calculator. The majority of
patients requiring supplemental oxygen were offered Remdesivir; eGFR cut-offs were not used as a strict exclusion criteria. All patients with
eGFR < 30mL/min/1.73m2 who received at least one dose of Remdesivir in hospital were included in the study. AKI was dened as at least a 1.5-
fold rise in creatinine from baseline per KDIGO criteria. CKD was dened as eGFR < 60mL/min/1.73m2 between 7-365 days prior to
admission. Patients with “stable CKD” did not meet criteria for AKI at the time of starting Remdesivir. ESRD was dened as requiring RRT > 3
months prior to hospitalization. The primary objectives were to describe changes in ALT, AST, and Bilirubin and serum creatinine during
Remdesivir therapy, and to report adverse effects attributed to Remdesivir. A Results: total of 41 patients with eGFR <30 ml/min per 1.73 m2 at
the time of Remdesivir initiation were included in the study. 27 patients were in intensive care, and 14 patients were mechanically ventilated at
the time of Remdesivir initiation. At the time of Remdesivir initiation, 30 patients were receiving RRT. 11 patients with eGFR <30 ml/min per
1.73 m2 were not on RRT at the time of starting Remdesivir. Four patients developed ALT more than the upper limit of normal and only two
patients developed ALT more than 5 times, that may be contributory to other factor also. In general, limited information is available Conclusion:
on the impact of SARS-CoV-2 infection in patients with eGFR less than 30. Impact of Remdesivir on these patients and their liver and kidney
functions are not well studied. Although the available clinical data are limited, but it shows that impact of Remdesivir on liver and kidney
function in patients of eGFR less than 30 is limited. However further studies are needed.
Aim: To determine QOL standards in patients with ESRD undergoing twice/week hemodialysis.
Methods: This was a multicenter cross-sectional study conducted in patients of either sex, aged above 18
years diagnosed with ESRD who were undergoing hemodialysis for at least three months in three hemodialysis centers. For
QOL assessment, patients underwent KDQOL questionnaire survey. KDQOL is a disease-specic QOL questionnaire. Results:
Total of 74 patients with ESRD (mean age: 54.7 years; men: 67.6%) undergoing hemodialysis enrolled. Overall, 53 (71.6%)
patients had improvement in their life in comparison to last year. Majority of patients reported no bodily pain (66.2%). Majority of
patients (68.9%) did not feel frustrated due to kidney disease. Total of 75.7% of patients did not feel like a burden on their family.
More than half of the patients reported they did not bother about dry skin (55.4%), sleep disturbance (66.2%), and problem with
access site (75.7%). Most of the patients reported that dialysis staff encouraged them to be as independent as possible (93.7%)
and support them in coping their kidney disease (93.3%). Conclusion: The present study was done to throw a light on the status
of QOL of Indian patients undergoing hemodialysis and might inspire the healthcare providers to endeavor for quality in
delivery of dialysis in the future.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.